Pharmaceuticals

ACE Inhibitors Market Developments And Opportunities Across 2026–2030

April 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The ACE Inhibitors Market During 2026–2030?

The ace inhibitors market has seen substantial growth in recent years. It is anticipated to increase from $7.41 billion in 2025 to $7.84 billion in 2026, at a compound annual growth rate (CAGR) of 5.8%. This historic growth can be ascribed to the rising prevalence of hypertension, increased awareness concerning cardiovascular diseases, the introduction of first-generation ace inhibitors, an expanding geriatric population, and advancements in drug formulation.

The ace inhibitors market size is set to experience robust expansion over the next few years. It is projected to increase to $10.11 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This growth during the forecast period is driven by factors such as the demand for personalized medicine, the incorporation of digital health solutions, the broadening of emerging markets, the creation of innovative ace inhibitor combinations, and the rise in home healthcare services. Significant trends anticipated for this period include personalized hypertension management, the adoption of telemedicine and remote patient monitoring, advancements in combination therapy, an increase in generic ace inhibitors, and the proliferation of home healthcare solutions.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10671&type=smp

What Leading Drivers Are Supporting The ACE Inhibitors Market Expansion?

The increasing occurrence of cardiac conditions is anticipated to stimulate the growth of the ACE inhibitors market moving forward. Cardiac disorders represent a collection of medical ailments that impact the heart or blood vessels, encompassing a broad spectrum of conditions such as coronary artery disease, heart failure, and arrhythmias. ACE inhibitors play a critical role in managing these disorders by inhibiting the angiotensin-converting enzyme, thereby decreasing vasoconstriction, sodium retention, and aldosterone secretion, which in turn improves cardiac function. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease escalated to 233.3 per 100,000 in 2024, marking a 4.0% increase from 224.4 per 100,000 in 2023. Thus, the rising incidence of cardiac disorders is propelling the expansion of the ACE inhibitors market.

Which Segment Classifications Are Used In The ACE Inhibitors Market Segment Analysis?

The ace inhibitors market covered in this report is segmented –

1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents

2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs

3) By Dosage Form: Oral Tablets, Oral Solutions

4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications

5) By End-Users: Hospitals, Online Drug Stores, Other End-Users

Subsegments:

1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril

2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril

3) By Phosphonate-Containing Agents: Fosinopril, Fosinopril Sodium, Fosinopril Calcium

What Emerging Trends Are Seen In The ACE Inhibitors Market?

Major companies within the ACE inhibitor market are escalating their efforts to introduce generic drugs, aiming to secure a competitive edge. A generic drug is a pharmaceutical product that possesses identical active ingredients, dosage, safety, strength, route of administration, and efficacy as its brand-name counterpart, yet it is typically offered at a reduced cost once the original patent lapses. For instance, in August 2023, Pharmascience Inc., a pharmaceutical company based in Canada, launched pms-PERINDOPRIL-INDAPAMIDE, a generic medication designed for the initial treatment of mild to moderate essential hypertension (high blood pressure) in adults. This combination product incorporates two active ingredients: perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor that assists in blood vessel relaxation, and indapamide, a chlorosulphamoyl diuretic that facilitates the elimination of surplus fluid and sodium from the body. Together, these components operate synergistically to efficiently lower blood pressure across a broad spectrum of patients. pms-PERINDOPRIL-INDAPAMIDE is provided in various dosage forms, including 2 mg, 4 mg, and 8 mg of perindopril erbumine, paired with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide, respectively.

Which Firms Are Contributing To The ACE Inhibitors Market Ecosystem?

Major companies operating in the ace inhibitors market are Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy’s Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

Get The Full ACE Inhibitors Market Report:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Which Region Holds The Highest Market Share In The ACE Inhibitors Market?

North America was the largest region in the ACE inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized ACE Inhibitors Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Browse Through More Reports Similar to the Global ACE Inhibitors Market 2026, By The Business Research Company

Ace Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

Enzyme Inhibitor Market Report 2026

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

Kinase Inhibitors Market Report 2026

https://www.thebusinessresearchcompany.com/report/kinase-inhibitors-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795